Episode 154: The Jefferson System and Alliance Oncology Legal Battle

Episode 154: The Jefferson System and Alliance Oncology Legal Battle

With Moshe Chasky and Lor Terzian of Alliance Cancer Specialists, Chadi explores the high-stakes lawsuit filed by Alliance against Jefferson Health and Thomas Jefferson University Hospitals, alleging anti-competitive practices that have reverberated throughout the healthcare industry. The duo provides insights into the case, its impact on patient care, and the broader implications for the healthcare landscape. Discover the motivations, legal intricacies, and ethical considerations behind this compelling legal battle that could reshape the future of healthcare in the United States.

Related Resources

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More